PARSIPPANY, NJ--(Marketwire - July 15, 2009) - The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, July 29, 2009 at 8:30 a.m. Eastern Time to discuss second quarter 2009 financial results and operational developments.
The conference call will be available via phone and webcast. The dial in information is listed below:
Domestic Dial In: 800-884-5695 International Dial In: 617-786-2960 Passcode for both dial in numbers: 64853162
Replay is available from 11:30 a.m. Eastern Time following the conference call through August 12, 2009. To hear a replay of the call, dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 37428278.
This call is being webcast and can be accessed at The Medicines Company website at www.themedicinescompany.com.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The Company
markets Angiomax® (bivalirudin) in the United States and other countries
for use in patients undergoing coronary angioplasty, and Cleviprex®
(clevidipine butyrate) injectable emulsion in the United States for the
reduction of blood pressure when oral therapy is not feasible or not
desirable. The Company also has two products in late stage development,
cangrelor, an investigational antiplatelet agent, and oritavancin, a
semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory
approval. The Company's pipeline also includes a serine protease
inhibitor, CU2010, in early-stage development. The Medicines Company's
website is www.themedicinescompany.com.
Contact:
Robyn Brown
Vice President, Investor Relations
The Medicines Company
973-290-6000
investor.relations@themedco.com
